TScan Therapeutics (NASDAQ:TCRX) Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of TScan Therapeutics (NASDAQ:TCRX) from a hold rating to a sell rating in a research note released on Saturday.

A number of other research firms have also weighed in on TCRX. Wedbush raised their price objective on TScan Therapeutics from $4.00 to $5.00 and gave the company an “outperform” rating in a research report on Thursday, March 5th. Morgan Stanley downgraded TScan Therapeutics from an “overweight” rating to an “equal weight” rating in a report on Friday, November 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of TScan Therapeutics in a research note on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $6.00.

TScan Therapeutics Trading Up 1.0%

NASDAQ:TCRX opened at $1.06 on Friday. The firm has a market capitalization of $60.31 million, a P/E ratio of -1.06 and a beta of 1.03. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.41 and a quick ratio of 8.41. TScan Therapeutics has a one year low of $0.88 and a one year high of $2.57. The company’s 50-day simple moving average is $1.08 and its 200 day simple moving average is $1.36.

TScan Therapeutics (NASDAQ:TCRX) last announced its earnings results on Wednesday, March 4th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.09. TScan Therapeutics had a negative net margin of 1,256.81% and a negative return on equity of 79.36%. The business had revenue of $2.57 million during the quarter, compared to the consensus estimate of $2.44 million. As a group, analysts forecast that TScan Therapeutics will post -1.12 EPS for the current fiscal year.

Insider Buying and Selling at TScan Therapeutics

In other news, major shareholder Lynx1 Capital Management Lp purchased 75,500 shares of TScan Therapeutics stock in a transaction that occurred on Monday, December 22nd. The stock was bought at an average price of $0.90 per share, with a total value of $67,950.00. Following the completion of the transaction, the insider directly owned 8,012,916 shares of the company’s stock, valued at approximately $7,211,624.40. The trade was a 0.95% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have purchased a total of 161,801 shares of company stock worth $145,621 over the last ninety days. 4.35% of the stock is owned by company insiders.

Institutional Trading of TScan Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Aberdeen Group plc increased its holdings in shares of TScan Therapeutics by 52.0% in the 3rd quarter. Aberdeen Group plc now owns 1,354,820 shares of the company’s stock worth $2,466,000 after purchasing an additional 463,372 shares in the last quarter. BVF Inc. IL raised its stake in shares of TScan Therapeutics by 6.9% in the second quarter. BVF Inc. IL now owns 5,226,074 shares of the company’s stock worth $7,578,000 after purchasing an additional 336,600 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of TScan Therapeutics by 37.5% during the fourth quarter. Renaissance Technologies LLC now owns 1,141,069 shares of the company’s stock valued at $1,141,000 after purchasing an additional 311,150 shares in the last quarter. Jane Street Group LLC boosted its position in shares of TScan Therapeutics by 377.5% during the fourth quarter. Jane Street Group LLC now owns 388,284 shares of the company’s stock valued at $388,000 after buying an additional 306,968 shares during the last quarter. Finally, Marshall Wace LLP boosted its position in shares of TScan Therapeutics by 627.5% during the fourth quarter. Marshall Wace LLP now owns 339,240 shares of the company’s stock valued at $339,000 after buying an additional 292,610 shares during the last quarter. 82.83% of the stock is currently owned by hedge funds and other institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.